Earlier this year, Tandem Diabetes Care announced a voluntary correction for certain t:slim X2 insulin pumps after identifying a potential defect that could interrupt insulin delivery and pose health ...
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors To Inquire About Securities Class Action Investigation - TNDM. NEW YORK, Oct. 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global ...
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.57, along with a high estimate of $51.00 and a low estimate of $10.35. A 38.75% drop is ...
On social media, Tandem Diabetes Care (Nasdaq:TNDM) said the launch of a new integration for its insulin pump system is near.
TipRanks on MSN
Tandem Diabetes resumed with a Hold at Stifel
Stifel resumed coverage of Tandem Diabetes (TNDM) with a Hold rating and $15 price target The firm is concerned about the company’s sequential ...
Truist analyst Richard Newitter raised the firm’s price target on Tandem Diabetes (TNDM) to $16 from $14 and keeps a Hold rating on the shares as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback